You are now viewing our public site. Back to Dashboard

Duchenne Muscular Dystrophy Part 2: Therapy Across the Lifespan

presented by Claudia Senesac, PT, PhD, PCS

Accrediting Body:

Target Audience:

Levels:
Disclosure Statement:

Satisfactory completion requirements: All disciplines must complete learning assessments to be awarded credit, no minimum score required unless otherwise specified within the course.

MedBridge is committed to accessibility for all of our subscribers. If you are in need of a disability-related accommodation, please contact [email protected]. We will process requests for reasonable accommodation and will provide reasonable accommodations where appropriate, in a prompt and efficient manner.

Accreditation Check:

Duchenne Muscular Dystrophy (DMD) is the most common childhood muscular dystrophy. Much of what we have known about this disease has been based on years of clinical observation, muscle biopsy, and other limited testing. Longitudinal studies and clinical trials are shaping our "new understanding" of this disease. The courses related to DMD will span pathophysiology, research, the development of therapy recommendations, and quality of life issues. Therapy recommendations are based on predictive models of biomarkers and function helping therapists and families plan for the future. Therapists play a critical role in caring for boys and young men with this disease.

Meet Your Instructor

Claudia Senesac, PT, PhD, PCS

Claudia Senesac is a clinical associate professor at University of Florida in the Doctor of Physical Therapy department. Her teaching responsibilities include functional anatomy dissection and pediatrics in physical therapy. She has over 37 years of pediatric clinical experience. She has been the owner and administrator of a pediatric physical therapy private practice since 1984…

Read full bio

Chapters & Learning Objectives

Download Learning Objectives Download Learning Objectives

Enter your information to unlock the learning objectives.

Thank you!

Download the learning objectives for Duchenne Muscular Dystrophy Part 2: Therapy Across the Lifespan.

Download Learning Objectives

1. Stages of Disease and Care Across Lifespan

In this chapter, the stages of the disease and transitions from one stage to the next will be introduced. Loss of the key functional skills will be discussed as it relates to key large muscle groups.

2. Pre-Symptomatic, Early, and Middle Ambulatory Stage

The early stages of the disease and transitions from pre-symptomatic to middle ambulatory stages. Understanding the impact of disease progression on the patient and family.

3. Late Ambulatory Stage and Early Wheelchair Stage

After watching this chapter, participants will be able to describe the late stage of walking and the early non-ambulatory stages of DMD. They will also be able to identify critical time periods for intervention.

4. Late Stage: Non-ambulatory

The chapter will describe the late non-ambulatory stages of DMD and identify critical time periods for intervention. We will also discuss important issues with the family as their child transitions from one stage to the next.

5. Outcome Measures

This chapter will identify function vs. impairment based outcomes used in assessing boys with DMD across the lifespan. Learners will also be able to identify and justify the use of appropriate outcomes for ambulatory and non-ambulatory boys with DMD for documentation.

6. Case Example

Assessing a patient with DMD through case description. Pulling together the important factors in the development of a plan of care that is individualized based on the results of observation, hands-on evaluation, report, and functional measures. Determining goals derived from the assessment.

Sign up to get free evidence-based articles, exclusive discounts, and insights from industry-leaders.

Join our newsletter to get the latest updates delivered straight to your inbox.

MedBridge blog posts and emails

Request a Demo

For groups of 5 or more, request a demo to learn about our solution and pricing for your organization. For other questions or support, visit our contact page.